Sequoia China, Morningside and Others Invest USD100m Series B for China’s Virtue Diagnostics
Source(s): Virtue Diagnostics
Virtue Diagnostics, a China-based in-vitro diagnostics company focused on cancer, infectious diseases and chronic diseases, raised a USD100m Series B from Sequoia China, Morningside Ventures and ORIZA Holdings, with follow-on from Lilly Asia Ventures and PerkinElmer Ventures. Read more